Go offline with the Player FM app!
Oct 24 2025 This Week in Cardiology
Manage episode 515446301 series 2794872
The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial
- PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037
 - SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939
 
II GLP-1 Mechanism of Action in CV Disease
- Analysis of SELECT Trial 10.1016/S0140-6736(25)01375-3 External Link
 - SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
 
III Statins and CAD Phenotype on CTA and Outcomes
- Interactions Between Statin Use, CAD Phenotypes on CTA https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018
 - Statin Use for Primary Prevention of CVD https://jamanetwork.com/journals/jama/fullarticle/2795522
 
IV HHF Endpoints in Heart Failure Trials
- The Problem with Hospitalization Endpoints in HF Trials https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070
 
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
380 episodes
Manage episode 515446301 series 2794872
The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial
- PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037
 - SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939
 
II GLP-1 Mechanism of Action in CV Disease
- Analysis of SELECT Trial 10.1016/S0140-6736(25)01375-3 External Link
 - SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
 
III Statins and CAD Phenotype on CTA and Outcomes
- Interactions Between Statin Use, CAD Phenotypes on CTA https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018
 - Statin Use for Primary Prevention of CVD https://jamanetwork.com/journals/jama/fullarticle/2795522
 
IV HHF Endpoints in Heart Failure Trials
- The Problem with Hospitalization Endpoints in HF Trials https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070
 
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
380 episodes
Alla avsnitt
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.